Alkermes plc buy melinda
Start price
19.06.17
/
50%
€51.55
Target price
05.07.17
€54.12
Performance (%)
5.28%
End price
05.07.17
€54.27
Summary
This prediction ended on 05.07.17 with a price of €54.27. The BUY prediction by melinda finished with a performance of 5.28%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alkermes plc | 1.500% | 1.500% | 21.453% | 8.473% |
| iShares Core DAX® | 0,41 % | 8,82 % | 12,26 % | 49,53 % |
| iShares Nasdaq 100 | 3,68 % | 10,82 % | 44,02 % | 96,25 % |
| iShares Nikkei 225® | 2,70 % | 15,25 % | 48,04 % | 64,69 % |
| iShares S&P 500 | 2,44 % | 7,93 % | 33,00 % | 67,57 % |
Comments by melinda for this prediction
In the thread Alkermes plc diskutieren
genehmigt (FDA)
Die US Food and Drug Administration (FDA) genehmigt hat ALKERMES des zweimonatigen Aristada (Aripiprazol lauroxil) extended-release injizierbare Suspension zur Behandlung von Schizophrenie.